These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 26408741)

  • 1. Drug-resistance Profile in Multiple-relapsed Childhood Acute Lymphoblastic Leukemia.
    Pogorzala M; Kubicka M; Rafinska B; Wysocki M; Styczynski J
    Anticancer Res; 2015 Oct; 35(10):5667-70. PubMed ID: 26408741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia.
    Styczynski J; Pieters R; Huismans DR; Schuurhuis GJ; Wysocki M; Veerman AJ
    Br J Haematol; 2000 Sep; 110(4):813-8. PubMed ID: 11054062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of prognostic value of in vitro drug resistance and bone marrow residual disease on day 15 of therapy in childhood acute lymphoblastic leukemia.
    Styczynski J; Piatkowska M; Jaworska-Posadzy A; Czyzewski K; Kubicka M; Kolodziej B; Kurylo-Rafinska B; Debski R; Pogorzala M; Wysocki M
    Anticancer Res; 2012 Dec; 32(12):5495-9. PubMed ID: 23225457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
    Hongo T; Yajima S; Sakurai M; Horikoshi Y; Hanada R
    Blood; 1997 Apr; 89(8):2959-65. PubMed ID: 9108416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.
    Den Boer ML; Harms DO; Pieters R; Kazemier KM; Gobel U; Körholz D; Graubner U; Haas RJ; Jorch N; Spaar HJ; Kaspers GJ; Kamps WA; Van der Does-Van den Berg A; Van Wering ER; Veerman AJ; Janka-Schaub GE
    J Clin Oncol; 2003 Sep; 21(17):3262-8. PubMed ID: 12947061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fludarabine, treosulfan and etoposide sensitivity and the outcome of hematopoietic stem cell transplantation in childhood acute myeloid leukemia.
    Styczynski J; Toporski J; Wysocki M; Debski R; Chybicka A; Boruczkowski D; Wachowiak J; Wojcik B; Kowalczyk J; Gil L; Balwierz W; Matysiak M; Krawczuk-Rybak M; Balcerska A; Sonta-Jakimczyk D
    Anticancer Res; 2007; 27(3B):1547-51. PubMed ID: 17595774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of combined fludarabine, treosulfan and mitoxantrone resistance profile in childhood acute myeloid leukemia.
    Styczynski J; Wysocki M; Dluzniewska A; Juraszewska E; Balwierz W; Czyzewski K; Wieczorek M; Olejnik I; Krawczuk-Rybak M; Kuzmicz M; Kowalczyk J; Stefaniak J; Badowska W; Sonta-Jakimczyk D; Szczepanski T; Matysiak M; Stanczak E; Malinowska I; Wachowiak J; Konatkowska B; Gil L; Balcerska A; Kapuscinska L; Szczepanek J; Kolodziej B; Rafinska B; Kubicka M
    Anticancer Res; 2008; 28(3B):1927-31. PubMed ID: 18630483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunophenotypic cell lineage and in vitro cellular drug resistance in childhood relapsed acute lymphoblastic leukaemia.
    Kaspers GJ; Wijnands JJ; Hartmann R; Huismans L; Loonen AH; Stackelberg A; Henze G; Pieters R; Hählen K; Van Wering ER; Veerman AJ
    Eur J Cancer; 2005 Jun; 41(9):1300-3. PubMed ID: 15869873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ex vivo drug resistance in childhood acute myeloid leukemia on relapse is not higher than at first diagnosis.
    Styczynski J; Wysocki M
    Pediatr Blood Cancer; 2004 Feb; 42(2):195-9. PubMed ID: 14752887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97].
    Janka-Schaub GE; Harms DO; den Boer ML; Veerman AJ; Pieters R
    Klin Padiatr; 1999; 211(4):233-8. PubMed ID: 10472556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individual tumor response testing in multiple relapsed acute myeloid leukemia in children.
    Styczynski J; Piatkowska M; Czyzewski K; Pogorzala M; Wysocki M
    Anticancer Res; 2013 Mar; 33(3):1189-93. PubMed ID: 23482801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.
    August KJ; Guest EM; Lewing K; Hays JA; Gamis AS
    Pediatr Blood Cancer; 2020 Mar; 67(3):e28062. PubMed ID: 31724803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.
    Zwaan CM; Kaspers GJ; Pieters R; Hählen K; Janka-Schaub GE; van Zantwijk CH; Huismans DR; de Vries E; Rots MG; Peters GJ; Jansen G; Creutzig U; Veerman AJ
    Blood; 2002 Jan; 99(1):245-51. PubMed ID: 11756178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo drug resistance profile in childhood acute myelogenous leukemia: no drug is more effective in comparison to acute lymphoblastic leukemia.
    Styczynski J; Wysocki M; Debski R; Juraszewska E; Malinowska I; Stanczak E; Ploszynska A; Stefaniak J; Mazur B; Szczepanski T
    Leuk Lymphoma; 2002 Sep; 43(9):1843-8. PubMed ID: 12685842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro cellular drug resistance adds prognostic information to other known risk-factors in childhood acute lymphoblastic leukemia.
    Lönnerholm G; Thörn I; Sundström C; Frost BM; Flaegstad T; Heyman M; Jonsson OG; Harila-Saari A; Madsen HO; Porwit A; Schmiegelow K; Söderhäll S; Wesenberg F; Vettenranta K; Larsson R; Forestier E
    Leuk Res; 2011 Apr; 35(4):472-8. PubMed ID: 20961616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro sensitivity of leukemic cells to nucleoside derivatives in childhood acute leukemias: good activity in leukemic relapses.
    Styczynski J; Wysocki M; Debski R; Czyzewski K; Balwierz W; Juraszewska E; Matysiak M; Malinowska I; Stanczak E; Sońta-Jakimczyk D; Szczepanski T; Wachowiak J; Konatkowska B; Balcerska A; Ploszynska A; Kowalczyk J; Stefaniak J; Badowska W; Wieczorek M; Olejnik I; Krawczuk-Rybak M; Kuzmicz M
    Neoplasma; 2005; 52(1):74-8. PubMed ID: 15739031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to glucocorticoids in childhood acute lymphoblastic leukemia: impact of relationship between ex vivo sensitivity and in vivo concentration on risk factor analysis.
    Styczynski J; Koltan A; Wysocki M
    Neoplasma; 2006; 53(2):168-73. PubMed ID: 16575474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia--implications for treatment of infants.
    Pieters R; den Boer ML; Durian M; Janka G; Schmiegelow K; Kaspers GJ; van Wering ER; Veerman AJ
    Leukemia; 1998 Sep; 12(9):1344-8. PubMed ID: 9737681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two groups of Philadelphia chromosome-positive childhood acute lymphoblastic leukemia classified by pretreatment multidrug sensitivity or resistance in in vitro testing.
    Hongo T; Okada S; Inoue N; Yamada S; Yajima S; Watanabe C; Fujii Y; Horikoshi Y
    Int J Hematol; 2002 Oct; 76(3):251-9. PubMed ID: 12416736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia.
    Zwaan CM; Kaspers GJ; Pieters R; Ramakers-Van Woerden NL; den Boer ML; Wünsche R; Rottier MM; Hählen K; van Wering ER; Janka-Schaub GE; Creutzig U; Veerman AJ
    Blood; 2000 Oct; 96(8):2879-86. PubMed ID: 11023525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.